01 — Identity

Name & Classification

L-Glutamine (Gln, Q) is the most abundant free amino acid in human plasma and skeletal muscle — and the most metabolically versatile amino acid in the body. It is classified as conditionally essential: under normal circumstances the body synthesizes enough; under physiological stress (surgery, illness, intense training, gut pathology) endogenous production is outpaced by demand and exogenous supplementation becomes critical.

Molecular formula: C₅H₁₀N₂O₃ — molecular weight 146.15 g/mol. The only amino acid carrying two nitrogen atoms in its side chain, making it the primary nitrogen shuttle between organs. Skeletal muscle stores roughly 60% of the body's free glutamine pool and serves as the main production site.

Unlike peptide therapies, L-Glutamine is an endogenous compound with no receptor downregulation, no tolerance mechanism, and no need to cycle. It is classified as GRAS (Generally Recognized As Safe) and used in infant formulas, ICU parenteral nutrition, and decades of clinical trials across critical care, oncology, and sports medicine.

02 — Research History

Origin & Key Milestones

1883

L-Glutamine first isolated from beet juice by Ernst Schulze and Ernst Bosshard. Decades of basic biochemistry followed establishing its central metabolic role.

1955

Harry Eagle (NIH) demonstrated glutamine is essential for mammalian cell culture survival — the first evidence it is uniquely critical for rapidly dividing cells like enterocytes and lymphocytes.

1970s–80s

Douglas Wilmore (Harvard/Brigham and Women's) pioneers clinical glutamine research in critical care. Landmark 1988 paper in Annals of Surgery establishes glutamine depletion as a key driver of gut failure in critically ill patients. Stehle et al. (1989, Lancet) demonstrate glutamine-supplemented TPN improves nitrogen balance and reduces hospital stay post-surgery.

1990s

Eric Newsholme (Oxford) publishes the "Glutamine Hypothesis" of exercise immunosuppression — prolonged exercise crashes plasma glutamine below 500 µmol/L, impairing lymphocyte function and explaining the "open window" of infection susceptibility in endurance athletes. Burn patient trials (Garrel, Wernerman) show 30–50% reduction in infection rates and mortality benefit.

2000s

Wave of gut permeability research. Glutamine positioned as primary tight junction stabilizer. Multiple trials in IBD, Crohn's, chemotherapy-induced mucositis, and short bowel syndrome. Short bowel syndrome becomes a major clinical use — reducing TPN dependence.

2009

Nicklin et al. (Cell): Definitive mechanistic paper establishing glutamine is required for leucine-dependent mTORC1 activation — the central muscle anabolic signaling pathway. Explains the synergy between glutamine and BCAAs.

2019

Zhou et al. (Gut): RCT of 106 patients with post-infectious IBS. Glutamine 15g/day × 8 weeks reduced composite symptom score by 60% vs. 22% placebo (p<0.001). Intestinal permeability normalized in 87% of glutamine group vs. 33% placebo. One of the strongest modern human trials.

Ongoing

Active research in long COVID gut symptoms, NAFLD gut-liver axis, and chemotherapy-induced peripheral neuropathy prevention. One of the most studied nutritional interventions in human clinical medicine.

03 — Mechanisms of Action

How It Works

🔥

ENTEROCYTE FUEL — PRIMARY GUT MECHANISM

Intestinal lining cells (enterocytes) cannot efficiently run on glucose — glutamine provides ~70% of their ATP via the TCA/Krebs cycle. Without adequate supply, villous atrophy occurs, tight junction proteins (occludin, claudin-1, ZO-1) are downregulated, and intestinal permeability increases. Glutamine directly upregulates these tight junction proteins and activates the EGF receptor pathway in enterocytes, driving mucosal repair.

🛡

IMMUNE CELL FUEL — LYMPHOCYTE & MACROPHAGE SUPPORT

Lymphocytes and macrophages depend on glutamine for nucleotide synthesis, glutathione production, and cytokine secretion. Plasma glutamine below 500 µmol/L (normal: 600–900 µmol/L) impairs immune function — this threshold is regularly crossed post-surgery, post-marathon, and in critical illness. Supplementation restores lymphocyte proliferation and macrophage phagocytic activity.

🔗

NITROGEN TRANSPORT — INTERORGAN SHUTTLE

The only amino acid carrying two nitrogens, glutamine is the body's primary nitrogen carrier. Skeletal muscle synthesizes it from BCAAs and ammonia, releasing it into circulation. The gut, kidneys, and immune system extract it for biosynthesis and nitrogen excretion. This makes glutamine the linchpin of nitrogen balance — critical for muscle preservation under catabolic stress — and a key player in acid-base homeostasis via renal ammonium excretion.

⚗️

GLUTATHIONE PRECURSOR — MASTER ANTIOXIDANT

Glutamine → Glutamate → Glutathione (GSH). Glutamine is the rate-limiting precursor for glutathione synthesis across most tissues. GSH is the body's primary intracellular antioxidant and detoxification molecule. Critically relevant for chemotherapy patients, athletes under oxidative load, and gut epithelium exposed to constant oxidative stress.

💪

mTORC1 ACTIVATION — ANABOLIC SIGNALING

Glutamine is required for mTOR Complex 1 activation. It facilitates leucine uptake via the bidirectional SLC7A5/ASCT2 transporter — leucine is mTOR's primary amino acid activator. No glutamine = leucine cannot enter cells = mTOR suppressed = protein synthesis attenuated. This is why glutamine + BCAAs is a foundational anabolic combination.

🧬

HSP70 INDUCTION — CELLULAR STRESS PROTECTION

Glutamine uniquely activates Heat Shock Protein 70 (HSP70) expression via the hexosamine biosynthetic pathway. HSP70 is a major cytoprotective protein that reduces cellular apoptosis, protects gut epithelium during ischemia-reperfusion injury, and suppresses inflammatory NF-κB signaling. This is particularly relevant in surgical recovery and intense training contexts.

⬇️

ANTI-CATABOLISM — PRESERVING MUSCLE UNDER STRESS

Under catabolic states, cortisol drives muscle protein breakdown to release glutamine for peripheral demand. Exogenous supplementation reduces this catabolic signal, maintains intramuscular glutamine pools, reduces urinary nitrogen losses, and attenuates cortisol-driven wasting. Athletes supplementing post-training show measurable reductions in 3-methylhistidine (a direct marker of muscle protein breakdown).

04 — Clinical Applications

Who Benefits Most

Leaky gut / intestinal hyperpermeability — restores tight junction proteins, fuels enterocyte repair

IBS / post-infectious IBS — Zhou 2019 RCT: 60% symptom reduction vs. 22% placebo

Crohn's disease / IBD — mucosal healing adjunct; reduces intestinal permeability markers

Post-antibiotic recovery — rebuilds mucosal integrity depleted by broad-spectrum antibiotics

Post-surgical recovery — reduces infectious complications, hospital length of stay, gut barrier failure

Burn patients — 50% reduction in gram-negative bacteremia; significant mortality benefit in severe burns

Endurance athletes — restores post-exercise immune function; reduces URTI incidence by ~3×

Muscle preservation — anti-catabolic; nitrogen balance maintenance; DOMS reduction

Chemotherapy patients — prevents mucositis with 5-FU, methotrexate, radiation-induced GI damage

Short bowel syndrome — reduces TPN dependence; primary pharmacological support for intestinal adaptation

05 — Dosing

Dose Reference — Oral Powder

LOW / MAINTENANCE

General gut maintenance, mild IBS, moderate training. Split AM + PM or take all at once fasted.

STANDARD

10g

Active gut healing, post-antibiotic recovery, regular athletic use. 5g AM fasted + 5g post-workout or pre-bed.

THERAPEUTIC / CLINICAL

20–40g

Crohn's, IBD flare, post-surgical, short bowel syndrome. Divide into 3–4 doses. Physician oversight recommended.

Context	Dose	Timing	Duration
MAINTENANCE	2.5–5 g/day	AM fasted	Ongoing / year-round
GUT HEALING	10–15 g/day	5g AM fasted + 5g pre-bed	8–12 weeks minimum
IBD / CROHN'S	0.5 g/kg/day	Divided 3–4× daily	8–16 weeks with monitoring
ATHLETIC RECOVERY	10–15 g/day	Post-workout + pre-bed	Continuous
POST-SURGICAL	20–30 g/day	Divided 4× daily	10–14 days min; up to 6 weeks
CHEMO MUCOSITIS	10–30 g/day	Divided throughout day	Duration of treatment course

Timing: Fasted AM dosing maximizes gut mucosal uptake (enterocytes are glutamine-depleted overnight). Post-workout dosing is critical for athletes — plasma glutamine drops 20–30% after intense training. Pre-bed dosing supports overnight gut repair and nitrogen retention. Food does not significantly impair absorption but may reduce peak plasma levels at very high doses.

Form: Oral powder is primary — dissolve in water or a shake. Tasteless, odorless, excellent bioavailability (>90% at standard doses). Capsules exist but are impractical at therapeutic doses (20–80 capsules/day). IV dipeptide form (L-alanyl-L-glutamine / Dipeptiven) is used in hospitals only — not for outpatient use. No injection required.

06 — Cycle Protocol

Cycle Length & Frequency

GUT HEALING COURSE

8–12 Weeks

Minimum for full mucosal restoration. Many practitioners extend to 3–6 months for severe IBD or long-standing leaky gut.

ATHLETIC / MAINTENANCE

Continuous

No cycling required. Glutamine has no receptor downregulation or tolerance mechanism. Year-round use at standard doses is well-supported.

PROTOCOL SUMMARY

Daily

FREQUENCY

AM Fasted

PREFERRED TIMING

Oral

ROUTE

None

BREAK NEEDED

Unlike peptides that require cycling to prevent receptor desensitization, L-Glutamine is an endogenous nutrient. Cycling off is not medically necessary at standard doses. However, for therapeutic gut healing protocols (high-dose, 8–12 weeks), a re-assessment phase is appropriate before extending — check zonulin, calprotectin, and symptom scores to evaluate mucosal response before continuing.

07 — Synergies & Stacks

What To Stack It With

BPC-157

THE ARCHITECT

The single most powerful combination for gut healing. BPC-157 drives angiogenesis and growth factor signaling (VEGF, EGF-R); glutamine provides the metabolic fuel for the enterocytes those signals are stimulating. Different cellular layers — maximum coverage.

KPV

THE FIREFIGHTER

KPV (alpha-MSH fragment) blocks NF-κB and suppresses the mucosal cytokine storm. Glutamine rebuilds the barrier KPV just cleared. KPV → reduces inflammation → glutamine → rebuilds tight junctions. Sequential and synergistic.

Zinc Carnosine

TIGHT JUNCTION COFACTOR

Zinc is a structural cofactor in tight junction assembly and wound healing. Zinc carnosine independently protects gut mucosa and inhibits H. pylori. Standard functional medicine gut protocol: glutamine 10g + zinc carnosine 75mg twice daily.

Colostrum

IgA + GROWTH FACTORS

Colostrum provides secretory IgA, IGF-1, TGF-beta, and lactoferrin — all gut-protective and immunomodulatory. Post-antibiotic gut repair: glutamine + colostrum is a foundational pairing in integrative medicine protocols.

BCAAs (esp. Leucine)

mTOR SYNERGY

Glutamine enables leucine uptake via SLC7A5 transporter. Leucine activates mTOR. No glutamine = blunted mTOR response to leucine. Together they produce a measurably stronger anabolic signal than either alone.

Probiotics

MICROBIOME SUPPORT

Probiotics restore microbiome diversity; glutamine maintains the mucosal surface the microbiome inhabits. Concurrent or sequential — glutamine first to restore barrier integrity, then probiotics to colonize the repaired surface.

FULL GUT REPAIR PROTOCOL

L-Glutamine (10–20g/day, fasted AM + pre-bed) + BPC-157 (500 mcg SC daily) + KPV (500 mcg SC or oral daily) + Zinc Carnosine (75mg 2×/day with food). Address all three layers simultaneously: fuel (glutamine) + regenerative signaling (BPC-157) + inflammation control (KPV) + structural cofactor (zinc carnosine).

08 — Mechanism Comparison

Glutamine vs. BPC-157 vs. KPV for Gut Healing

Understanding why these three work together requires knowing what layer each one targets.

Feature	L-Glutamine	BPC-157	KPV
Class	Amino acid	15-AA synthetic peptide	Tripeptide (MSH fragment)
Layer targeted	Metabolic fuel	Growth signaling	Inflammation control
Tight junction effect	Direct — upregulates occludin, claudin-1, ZO-1 expression	Indirect — promotes vascularity that enables TJ restoration	Reduces inflammatory drivers of TJ breakdown
Angiogenesis	Minimal	MAJOR — VEGF-driven new vessel formation	Minimal
Immune effect	Systemic — fuels lymphocytes, macrophages	Local gut-associated lymphoid tissue repair	Anti-inflammatory — reduces IL-6, TNF-α, NF-κB
Speed of action	Hours–days (barrier), weeks (full mucosal)	Signaling hours; tissue regeneration weeks	Anti-inflammatory effect hours–days
Human clinical evidence	Extensive — hundreds of RCTs	Primarily animal; limited human RCTs	Primarily preclinical
Route	Oral powder	Injectable SC/IM	Oral or injectable
Role in stack	THE FUEL	THE ARCHITECT	THE FIREFIGHTER

Why you need all three: KPV clears the inflammatory environment. BPC-157 signals the regenerative growth cascade. Glutamine provides continuous metabolic fuel to the enterocytes both are stimulating. No single agent addresses all three layers. This is why the triple stack is clinically superior to any individual agent for severe gut pathology.

09 — Safety Profile

Contraindications & Safety Notes

▸ General Safety

Excellent safety record. GRAS status. Used in infant formulas, ICU parenteral nutrition, and clinical trials at up to 40g/day. Most common side effects at high doses are GI (bloating, cramping, nausea) — titrate up gradually. Standard doses (5–15g/day) are very well tolerated.

▸ Critical Contraindications

Hepatic Encephalopathy / Decompensated Liver Disease — CONTRAINDICATED. In liver failure, glutamine deamination by gut bacteria generates excess ammonia that the damaged liver cannot clear. Can worsen encephalopathy. Absolute contraindication.

Bipolar Disorder / Schizophrenia / Seizure Disorders — SIGNIFICANT CAUTION. Glutamine is metabolized to glutamate (excitatory neurotransmitter). High doses may theoretically precipitate manic episodes or worsen schizophrenic symptoms via glutamate excess. May be pro-convulsant at high doses in epilepsy. Do not use high-dose glutamine in these populations without specialist supervision.

Cancer — Discuss with Oncologist. Cancer cells are glutamine-avid (Warburg-adjacent metabolism). Current clinical evidence does not support restricting glutamine in cancer patients receiving standard therapy — benefit-risk ratio is favorable — but this remains an active research area. Always discuss with treating oncologist.

▸ Common Side Effects (dose-dependent)

Effect	Dose Threshold	Management
GI discomfort (bloating, nausea)	Usually >20g/day	Titrate up gradually; divide doses
Mild headache	Variable; possibly glutamate elevation	Reduce dose; split across day
Loose stools	Very high doses only	Rare at standard doses; reduce if occurs

No formal upper limit established by the Institute of Medicine. Practical therapeutic upper limit: 0.5 g/kg/day for oral use. Human studies have used up to 40–45g/day without serious adverse events.

10 — Lab Monitoring

Biomarkers & Recommended Tests

▸ Gut Healing — Primary Markers

Biomarker	Lab Test	Clinical Range	Optimal (on protocol)
Zonulin Tight junction disruptor — leaky gut marker	Serum or Stool Zonulin	CLINICAL<107 ng/mL	OPTIMAL<40 ng/mL; trending down
Calprotectin Neutrophil activity in gut mucosa	Stool Calprotectin	CLINICAL<50 µg/g	OPTIMAL<25 µg/g
Lactulose/Mannitol Ratio Direct intestinal permeability test	Urine L/M Ratio Test	CLINICAL<0.03	OPTIMALTrending to <0.01 during protocol
Plasma Glutamine Directly confirms depletion/repletion	Plasma Amino Acid Panel	CLINICAL570–900 µmol/L	OPTIMAL700–900 µmol/L

▸ Inflammation & Safety

Biomarker	Lab Test	Clinical Range	Optimal
hsCRP	High-sensitivity CRP	CLINICAL<3.0 mg/L	OPTIMAL<0.5 mg/L
Liver Function ALT, AST, bilirubin — for high-dose protocols	CMP / LFTs	CLINICALAST 10–40 / ALT 7–56 U/L	OPTIMALAST <26 / ALT <26 U/L
Serum Ammonia Check if liver disease suspected	Serum NH₃	CLINICAL11–32 µmol/L	OPTIMAL<20 µmol/L; no rising trend
CBC Lymphocyte count reflects immune status	Complete Blood Count	CLINICALStandard ranges	OPTIMALLymphocytes 1.5–3.5 × 10⁹/L

READY TO ADD THIS TO YOUR STACK?

Drop L-Glutamine into your protocol tracker — dosing pre-filled, timing set, cycle ready.

ADD TO MY PROTOCOL →

Saves your dose selection. Returns you here after.

⚠ L-Glutamine is well-studied and generally safe for most adults at standard doses. High-dose therapeutic protocols (>20g/day) warrant baseline CMP and periodic monitoring. Contraindicated in hepatic encephalopathy; use with caution in seizure disorders and mood disorders. Always discuss with a healthcare provider before beginning any therapeutic protocol.

11 — Key Studies

Landmark Research

STEHLE ET AL. 1989 — LANCET

Glutamine-supplemented TPN vs. standard TPN in post-surgical patients. Glutamine group: improved nitrogen balance, significantly reduced hospital stay. One of the first major RCTs establishing clinical glutamine efficacy.

GARREL ET AL. 2003 — CRITICAL CARE MEDICINE

RCT in severe burn patients. Oral glutamine 0.5g/kg/day vs. placebo. Glutamine group: 50% reduction in gram-negative bacteremia, significantly lower mortality. Clinical standard of care in major burn centers emerged from this line of research.

CASTELL ET AL. 1996 — INT'L J SPORTS MEDICINE

Marathon runners supplemented with glutamine immediately post-race had 1/3 the incidence of upper respiratory infections over 7 days vs. placebo. Plasma glutamine restoration confirmed. Defines the athletic immune support use case.

NICKLIN ET AL. 2009 — CELL

Definitive mechanistic paper: glutamine is required for leucine-dependent mTORC1 activation via bidirectional SLC7A5/SLC3A2 transporter exchange. Explains the molecular basis of glutamine's anabolic signaling role. Highly cited foundational paper.

PENG ET AL. 2011 — CLINICAL NUTRITION

RCT comparing oral glutamine (0.5g/kg/day) vs. whey protein in Crohn's disease over 8 weeks. Glutamine group showed superior mucosal healing on endoscopy with significant reduction in tight junction protein loss.

ZHOU ET AL. 2019 — GUT (BMJ)

RCT, 106 patients, post-infectious IBS. Glutamine 15g/day × 8 weeks: composite GI symptom score reduced 60% vs. 22% placebo (p<0.001). Intestinal permeability (L/M ratio) normalized in 87% of glutamine group vs. 33% placebo. One of the most impactful modern gut glutamine trials. Published in a top-tier GI journal.

LIANG ET AL. 2018 — META-ANALYSIS, CLINICAL NUTRITION

14 RCTs analyzed. Oral glutamine significantly reduced chemotherapy-induced mucositis grade ≥3 (relative risk 0.50, 95% CI 0.36–0.69) and reduced treatment delays due to mucositis. Supports use as adjunct during chemotherapy.

12 — Storage

Storage & Stability

Condition	Guideline
Temperature (powder)	Room temperature, below 25°C / 77°F — no refrigeration required or recommended (condensation risk)
Moisture	Keep sealed; glutamine is hygroscopic — humidity causes clumping and accelerated degradation. Use silica desiccant packets in large containers.
Shelf life (sealed powder)	2+ years in a cool, dry, sealed container
In solution	Use within 1–2 hours of dissolving — glutamine degrades in water (cyclizes to pyroglutamate), especially at high temperatures. Do not pre-mix and store.
Light	Not a significant degradation factor for dry powder; minimal concern

L-Glutamine is the least stable common amino acid in aqueous solution. Always mix and drink immediately. Dry powder in a sealed, moisture-free container is stable for years. Unlike peptides, no refrigeration is required for the dry form.

READY TO ADD THIS TO YOUR STACK?

Drop L-Glutamine into your protocol tracker — dosing pre-filled, timing set, cycle ready.

ADD TO MY PROTOCOL →

Saves your dose selection. Takes you right back here after.

⚠ RESEARCH & EDUCATIONAL USE ONLY. L-Glutamine is a dietary supplement, not a drug approved to treat or cure any disease. This reference is for educational purposes. Information presented is based on published research and does not constitute medical advice. Consult a licensed healthcare provider before beginning any supplement protocol, particularly at therapeutic doses.